IFNG and cancer: In the large-scale analysis of RSI across 11 major cancer types, we identified that RSI was related to various immune-relevant genomic and molecular features, and low RSI were associated with dominant IFN-γ signalling response and predicted therapeutic efficacy of PD-1 blockade.